Logo image of RMTI

ROCKWELL MEDICAL INC (RMTI) Stock Fundamental Analysis

NASDAQ:RMTI - US7743743004 - Common Stock

1.24 USD
-0.06 (-4.62%)
Last: 8/26/2025, 8:00:22 PM
1.3 USD
+0.06 (+4.84%)
After Hours: 8/26/2025, 8:00:22 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to RMTI. RMTI was compared to 185 industry peers in the Health Care Equipment & Supplies industry. The financial health of RMTI is average, but there are quite some concerns on its profitability. RMTI does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

RMTI had negative earnings in the past year.
In the past year RMTI had a positive cash flow from operations.
RMTI had negative earnings in each of the past 5 years.
RMTI had negative operating cash flow in 4 of the past 5 years.
RMTI Yearly Net Income VS EBIT VS OCF VS FCFRMTI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

With a decent Return On Assets value of -3.99%, RMTI is doing good in the industry, outperforming 64.86% of the companies in the same industry.
Looking at the Return On Equity, with a value of -6.90%, RMTI is in the better half of the industry, outperforming 66.49% of the companies in the same industry.
Industry RankSector Rank
ROA -3.99%
ROE -6.9%
ROIC N/A
ROA(3y)-19.01%
ROA(5y)-32.81%
ROE(3y)-57.83%
ROE(5y)-310.02%
ROIC(3y)N/A
ROIC(5y)N/A
RMTI Yearly ROA, ROE, ROICRMTI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

1.3 Margins

RMTI has a Gross Margin of 17.52%. This is amonst the worse of the industry: RMTI underperforms 82.16% of its industry peers.
RMTI's Gross Margin has improved in the last couple of years.
RMTI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 17.52%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y30.04%
RMTI Yearly Profit, Operating, Gross MarginsRMTI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40

More info and screens

5

2. Health

2.1 Basic Checks

RMTI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for RMTI has been increased compared to 1 year ago.
The number of shares outstanding for RMTI has been increased compared to 5 years ago.
Compared to 1 year ago, RMTI has an improved debt to assets ratio.
RMTI Yearly Shares OutstandingRMTI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
RMTI Yearly Total Debt VS Total AssetsRMTI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -7.44, we must say that RMTI is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of RMTI (-7.44) is worse than 72.43% of its industry peers.
The Debt to FCF ratio of RMTI is 3.93, which is a good value as it means it would take RMTI, 3.93 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.93, RMTI belongs to the top of the industry, outperforming 82.70% of the companies in the same industry.
A Debt/Equity ratio of 0.33 indicates that RMTI is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.33, RMTI perfoms like the industry average, outperforming 46.49% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.33
Debt/FCF 3.93
Altman-Z -7.44
ROIC/WACCN/A
WACC8.43%
RMTI Yearly LT Debt VS Equity VS FCFRMTI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

RMTI has a Current Ratio of 2.89. This indicates that RMTI is financially healthy and has no problem in meeting its short term obligations.
RMTI has a Current ratio (2.89) which is comparable to the rest of the industry.
A Quick Ratio of 2.51 indicates that RMTI has no problem at all paying its short term obligations.
RMTI has a Quick ratio of 2.51. This is in the better half of the industry: RMTI outperforms 60.54% of its industry peers.
Industry RankSector Rank
Current Ratio 2.89
Quick Ratio 2.51
RMTI Yearly Current Assets VS Current LiabilitesRMTI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

2

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 64.91% over the past year.
Looking at the last year, RMTI shows a decrease in Revenue. The Revenue has decreased by -6.79% in the last year.
RMTI shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.61% yearly.
EPS 1Y (TTM)64.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-655.56%
Revenue 1Y (TTM)-6.79%
Revenue growth 3Y17.9%
Revenue growth 5Y10.61%
Sales Q2Q%-37.79%

3.2 Future

The Earnings Per Share is expected to decrease by -89.45% on average over the next years. This is quite bad
The Revenue is expected to decrease by -9.82% on average over the next years.
EPS Next Y-750%
EPS Next 2Y-151.28%
EPS Next 3Y-89.45%
EPS Next 5YN/A
Revenue Next Year-31.95%
Revenue Next 2Y-13.1%
Revenue Next 3Y-9.82%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
RMTI Yearly Revenue VS EstimatesRMTI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M 100M
RMTI Yearly EPS VS EstimatesRMTI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -2 -4 -6

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

RMTI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RMTI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RMTI Price Earnings VS Forward Price EarningsRMTI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of RMTI indicates a somewhat cheap valuation: RMTI is cheaper than 70.27% of the companies listed in the same industry.
91.35% of the companies in the same industry are more expensive than RMTI, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 15.91
EV/EBITDA 31.49
RMTI Per share dataRMTI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2 2.5

4.3 Compensation for Growth

A cheap valuation may be justified as RMTI's earnings are expected to decrease with -89.45% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-151.28%
EPS Next 3Y-89.45%

More info and screens

0

5. Dividend

5.1 Amount

RMTI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ROCKWELL MEDICAL INC

NASDAQ:RMTI (8/26/2025, 8:00:22 PM)

After market: 1.3 +0.06 (+4.84%)

1.24

-0.06 (-4.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-14 2025-08-14/bmo
Earnings (Next)11-10 2025-11-10
Inst Owners20.76%
Inst Owner Change-15.74%
Ins Owners4.42%
Ins Owner Change7.69%
Market Cap42.69M
Analysts82.5
Price Target4.08 (229.03%)
Short Float %0.35%
Short Ratio0.33
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.76%
Min EPS beat(2)1.96%
Max EPS beat(2)21.57%
EPS beat(4)3
Avg EPS beat(4)53.92%
Min EPS beat(4)-198.04%
Max EPS beat(4)390.2%
EPS beat(8)6
Avg EPS beat(8)44.81%
EPS beat(12)9
Avg EPS beat(12)35.07%
EPS beat(16)12
Avg EPS beat(16)34.77%
Revenue beat(2)1
Avg Revenue beat(2)1.34%
Min Revenue beat(2)-3.53%
Max Revenue beat(2)6.2%
Revenue beat(4)3
Avg Revenue beat(4)2.42%
Min Revenue beat(4)-3.53%
Max Revenue beat(4)6.2%
Revenue beat(8)6
Avg Revenue beat(8)2.54%
Revenue beat(12)8
Avg Revenue beat(12)2.49%
Revenue beat(16)9
Avg Revenue beat(16)-0.35%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)18.18%
EPS NQ rev (3m)-350%
EPS NY rev (1m)14.63%
EPS NY rev (3m)-6.06%
Revenue NQ rev (1m)1.46%
Revenue NQ rev (3m)-23.92%
Revenue NY rev (1m)0.21%
Revenue NY rev (3m)0.08%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.49
P/FCF 15.91
P/OCF 12.21
P/B 1.4
P/tB 2.18
EV/EBITDA 31.49
EPS(TTM)-0.06
EYN/A
EPS(NY)-0.13
Fwd EYN/A
FCF(TTM)0.08
FCFY6.29%
OCF(TTM)0.1
OCFY8.19%
SpS2.55
BVpS0.88
TBVpS0.57
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -3.99%
ROE -6.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 17.52%
FCFM 3.05%
ROA(3y)-19.01%
ROA(5y)-32.81%
ROE(3y)-57.83%
ROE(5y)-310.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y30.04%
F-Score6
Asset Turnover1.67
Health
Industry RankSector Rank
Debt/Equity 0.33
Debt/FCF 3.93
Debt/EBITDA 11.07
Cap/Depr 37.16%
Cap/Sales 0.92%
Interest Coverage N/A
Cash Conversion 390.29%
Profit Quality N/A
Current Ratio 2.89
Quick Ratio 2.51
Altman-Z -7.44
F-Score6
WACC8.43%
ROIC/WACCN/A
Cap/Depr(3y)323.45%
Cap/Depr(5y)234.89%
Cap/Sales(3y)5.5%
Cap/Sales(5y)3.81%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)64.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-655.56%
EPS Next Y-750%
EPS Next 2Y-151.28%
EPS Next 3Y-89.45%
EPS Next 5YN/A
Revenue 1Y (TTM)-6.79%
Revenue growth 3Y17.9%
Revenue growth 5Y10.61%
Sales Q2Q%-37.79%
Revenue Next Year-31.95%
Revenue Next 2Y-13.1%
Revenue Next 3Y-9.82%
Revenue Next 5YN/A
EBIT growth 1Y58.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-246.39%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y134.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y147.84%
OCF growth 3YN/A
OCF growth 5YN/A